Daprodustat

Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

Product Specifications

CAS Number

[960539-70-2]

Product Name Alternative

GSK1278863

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

HIF/HIF Prolyl-Hydroxylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Daprodustat.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)CNC(C(C(N1C2CCCCC2)=O)C(N(C3CCCCC3)C1=O)=O)=O

Molecular Formula

C19H27N3O6

Molecular Weight

393.43

Precautions

H315, H319, H335

References & Citations

[1]Brigandi RA, et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. Am J Kidney Dis. 2016 Jun;67 (6) :861-71|[2]Hara K, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30 (6) :410-8